RAD18: A Potential Drug Target Or Biomarker for Disease (G56852)

Target Name: RAD18

NCBI ID: G56852

RAD18

RAD18: A Potential Drug Target Or Biomarker for Disease

RAD18 (regulatory associated protein RAD18) is a protein that plays a crucial role in cellular signaling pathways. It is a ubiquitin-protein ligase that is involved in the degradation of intracellular proteins, which is essential for maintaining tissue homeostasis and cell survival. The degradation of intracellular proteins is a critical process that helps to prevent the buildup of unnecessary or harmful proteins, which can lead to a range of cellular signaling pathways that are involved in cell growth, differentiation, and death.

Recent studies have identified RAD18 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because RAD18 is involved in the regulation of many cellular processes that are important for disease progression, and may be a useful target for therapeutic intervention.

Disease-specific mechanisms

RAD18 is involved in the regulation of several key signaling pathways that are involved in disease progression. One of the most well-studied pathways is the regulation of cell death, which is a critical process that helps to remove damaged or dysfunctional cells from the body.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the buildup of damaged or dysfunctional proteins is thought to contribute to the progression of the disease. RAD18 is involved in the regulation of the degradation of these proteins, which is essential for maintaining tissue homeostasis and cell survival.

In cancer, RAD18 is involved in the regulation of the metastatic process. Studies have shown that RAD18 is involved in the regulation of the migration and invasion of cancer cells, which is essential for their ability to spread throughout the body and form new tumors.

In autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, the buildup of abnormal antibodies or inflammation in the body is thought to contribute to the development and progression of the disease. RAD18 is involved in the regulation of the immune response, which is essential for maintaining tissue homeostasis and immune function.

Drug targeting

Several studies have identified potential drug targets for RAD18, including small molecules, antibodies, and other therapeutic agents. One of the most promising approaches is the use of small molecules that can modulate RAD18 activity.

Studies have shown that small molecules such as inhibitors of the ubiquitin-protein ligase activity of RAD18 can be effective in reducing the levels of intracellular proteins that are targeted for degradation by RAD18. These small molecules have been shown to be effective in a variety of cellular models, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting RAD18 is the use of antibodies that are specific for RAD18. Studies have shown that antibodies against RAD18 have been effective in reducing the levels of intracellular proteins that are targeted for degradation by RAD18, and may be a promising approach for therapeutic intervention.

Conclusion

In conclusion, RAD18 is a protein that plays a crucial role in cellular signaling pathways and is involved in the regulation of several key processes that are essential for tissue homeostasis and cell survival. The buildup of damaged or dysfunctional proteins, as well as the regulation of cell death, metastasis, and immune response, makes RAD18 a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of RAD18 in disease progression and to develop effective therapeutic interventions.

Protein Name: RAD18 E3 Ubiquitin Protein Ligase

Functions: E3 ubiquitin-protein ligase involved in postreplication repair of UV-damaged DNA. Postreplication repair functions in gap-filling of a daughter strand on replication of damaged DNA. Associates to the E2 ubiquitin conjugating enzyme UBE2B to form the UBE2B-RAD18 ubiquitin ligase complex involved in mono-ubiquitination of DNA-associated PCNA on 'Lys-164'. Has ssDNA binding activity

The "RAD18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAD18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets